ERBB2 and breast carcinoma: Trastuzumab deruxtecan (T-DXd), through improved linker design and a more potent topoisomerase I inhibitor, has demonstrated broader applicability, especially in patients with HER2-low breast cancer, by killing adjacent HER2-negative cells via the “bystander effect”.